FDA approves Cuvrior for treatment of adults with stable Wilson’s disease

FDA approves Cuvrior for treatment of adults with stable Wilson’s disease

Orphalan announced FDA approval of Cuvrior for the treatment of adults with stable Wilson’s disease who are de-coppered and tolerant to penicillamine, according to a company press release.Cuvrior (trientine tetrahydrochloride, Orphalan) recently demonstrated noninferiority to penicillamine by measurement of non-ceruloplasmin copper in a global, phase 3 trial; penicillamine is currently approved as a first-line treatment for Wilson’s with approximately one-third of patients developing intolerance.“As a physician, I have seen firsthand how Wilson’s disease impacts theRead More